AbCellera Biologics

ABCL

Market cap $1.08B

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago.

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in March and April 2026.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026.

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Bruker Reach Global Settlement of Patent Litigation.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript